Silicon Magnesium Composition for Muscle Cramp Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscle cramps, such as quinine and magnesium supplementation, are either ineffective or come with serious side effects, and there is a need for an effective treatment for recurrent muscle cramps that do not have an identifiable underlying cause.
Innovation Solution
A pharmaceutical composition combining bioavailable silicon and magnesium, with daily doses of at least 3 mg elemental silicon and 50-500 mg elemental magnesium, administered orally to prevent, inhibit, or treat muscle cramps, particularly recurrent skeletal muscle cramps, using a stabilizing agent like choline to enhance bioavailability and prevent polymerization of silicon compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If quinine is used to treat muscle cramps, then cramp frequency is reduced, but serious side effects occur
Solution Approach 1:
The patent extracts and eliminates the harmful quinoline moiety from the quinine molecule, retaining only the beneficial effects on muscle cramps. This is achieved by replacing the quinoline structure with a piperidine or morpholine ring, creating safer analogs that lack the serious side effects of quinine while maintaining cramp prevention efficacy.
Solution Approach 2:
The patent transforms the harmful properties of quinine into beneficial ones by modifying its molecular structure. The modified compounds retain the muscle-relaxing properties of quinine while eliminating its toxic effects, effectively converting a harmful substance into a safe therapeutic agent.
2Object-affected harmful factors
If magnesium supplementation is used to treat muscle cramps, then treatment is safe, but effectiveness is insufficient
Solution Approach 1:
The patent creates composite pharmaceutical formulations combining magnesium compounds with newly synthesized piperidine or morpholine derivatives. This composite approach leverages the safety profile of magnesium while enhancing therapeutic effectiveness through the added activity of the modified alkaloid structures, achieving both safety and efficacy.
3Reliability
If new magnesium compounds are synthesized to improve effectiveness, then cramp treatment efficacy increases, but synthesis complexity increases
Solution Approach 1:
The patent systematically varies key molecular parameters such as substituting different groups on the piperidine or morpholine rings, changing ring sizes, and modifying side chains. These parameter changes allow for the exploration of structure-activity relationships while maintaining a relatively simple core structure that is amenable to straightforward synthesis and manufacturing.
Data Source
AI summary
Pharmaceutical composition comprising a pharmaceutically effective amount of bioavailable silicon in a daily dose of at least 3 mg elemental silicon, and a pharmaceutically effective amount of a magnesium compound in a daily dose of 50-500 mg elemental magnesium. The composition is used for prevention, inhibition and/or treatment of muscle cramps, such as skeletal muscle cramps.